Gadolinium-based contrast agents (GBCAs) used in MRI and angiography contain a chelated form of the toxic heavy metal that was assumed to clear the body shortly after intravenous administration. [1] ...
In a new practice advisory, an international team of experts discussed the use of gadolinium-based contrast agents (GBCAs), an alternative to iodinated contrast media, in interventional pain ...
Compared to group I GBCAs, group II GBCAs appear safe for use in patients with severe kidney disease. In a recent analysis, the risk of NSF in patients with stage 4 or 5 CKD was less than 0.07% with ...
DEAR DR. ROACH: Due to a slight genetic risk of breast cancer (my Tyrer-Cuzick Model score was 20.6%), my doctor wants me to get breast MRIs with contrast annually. I am concerned about long-term ...
PRINCETON, N.J., March 31, 2017 /PRNewswire/ -- Guerbet LLC., subsidiary of Guerbet Group (FR0000032526 GBT), the global specialist in contrast products and solutions for medical imaging, takes note ...
DEAR DR. ROACH: My primary care doctor has ordered that I get an MRI scan with and without contrast dye. I have been having head pain every day in one single spot behind my right eye. My question is, ...
Contrast materials can help highlight areas of interest in MRI scans. Contrast injections may cause side effects like mild rashes and hives, but, in rare instances, it is also possible for a person to ...
Gadopiclenol carries a Boxed Warning associated with an increased risk of nephrogenic systemic fibrosis among patients with impaired elimination of the drugs. The approval of gadopiclenol was based on ...
Gadolinium-based contrast agents alone don't cause patients to develop nephrogenic systemic fibrosis
Even at very high doses, gadolinium-based contrast agents alone are not sufficient to cause nephrogenic systemic fibrosis (NSF) in patients with kidney problems, according to a study performed at the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback